Among MSI-H tumors, nonrecurrent cases showed higher expression of immune response–related genes including FCGR1A, FCGR3B, GZMB, CD3G, and CCL18 as well as of immune checkpoint genes such as TIGIT and LAG3 (Fig. 4a,b and Supplementary Table 2), suggesting that an adverse change in the tumor immune microenvironment may be associated with recurrence. Here, FCGR1A is linked to neoplasm.